Search research articles
Contact Us
Filters
Showing results (511-520 of 1,063) with videos related to
Page
of 107
Sort By:
Frontiers in Genetics
|
October 18, 2021
Corrigendum: ALG1-CDG Caused by Non-Functional Alternative Splicing Involving a Novel Pathogenic Complex Allele
Carlos Alberto González-Domínguez, Moisés O Fiesco-Roa, Samuel Gómez-Carmona, et al.
Frontiers in Genetics
|
September 27, 2021
ALG1-CDG Caused by Non-functional Alternative Splicing Involving a Novel Pathogenic Complex Allele
Carlos Alberto González-Domínguez, Moisés O Fiesco-Roa, Samuel Gómez-Carmona, et al.
Journal of Medicinal Chemistry
|
September 7, 2021
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
M Raymond V Finlay, Peter Barton, Sue Bickerton, et al.
Journal of Inherited Metabolic Disease
|
July 19, 2020
International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and management
Ruqaiah Altassan, Silvia Radenkovic, Andrew C Edmondson, et al.
Cancer Cell
|
October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2019
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Jason Willis, Martina I Lefterova, Alexander Artyomenko, et al.
Cancer Cell
|
March 19, 2020
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
Brain : a Journal of Neurology
|
April 16, 2020
Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function
Monica Zilmer, Andrew C Edmondson, Sumeet A Khetarpal, et al.
Journal of Medicinal Chemistry
|
June 15, 2019
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models
M Raymond V Finlay, Mark Anderton, Andrew Bailey, et al.
Page
of 107
Search research articles
Search
Showing results (511-520 of 1,063) with videos related to
Sort By:
Page
of 107
Frontiers in Genetics
|
October 18, 2021
Corrigendum: ALG1-CDG Caused by Non-Functional Alternative Splicing Involving a Novel Pathogenic Complex Allele
Carlos Alberto González-Domínguez, Moisés O Fiesco-Roa, Samuel Gómez-Carmona, et al.
Frontiers in Genetics
|
September 27, 2021
ALG1-CDG Caused by Non-functional Alternative Splicing Involving a Novel Pathogenic Complex Allele
Carlos Alberto González-Domínguez, Moisés O Fiesco-Roa, Samuel Gómez-Carmona, et al.
Journal of Medicinal Chemistry
|
September 7, 2021
Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance
M Raymond V Finlay, Peter Barton, Sue Bickerton, et al.
Journal of Inherited Metabolic Disease
|
July 19, 2020
International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and management
Ruqaiah Altassan, Silvia Radenkovic, Andrew C Edmondson, et al.
Cancer Cell
|
October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2019
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Jason Willis, Martina I Lefterova, Alexander Artyomenko, et al.
Cancer Cell
|
March 19, 2020
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2021
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Sylvia Adams, Megan Othus, Sandip Pravin Patel, et al.
Brain : a Journal of Neurology
|
April 16, 2020
Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function
Monica Zilmer, Andrew C Edmondson, Sumeet A Khetarpal, et al.
Journal of Medicinal Chemistry
|
June 15, 2019
Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models
M Raymond V Finlay, Mark Anderton, Andrew Bailey, et al.
Page
of 107